AQST · Aquestive Therapeutics Inc.
The AI's read
Aquestive reported positive human factors and pharmacokinetic validation study results for Anaphylm that directly address FDA usability and PK concerns from its January 2026 Complete Response Letter. Those fixes lower the biggest regulatory hurdles ahead of a planned Q3 2026 NDA resubmission. The market already reacted, with AQST up ~13.3% intraday and RSI near 69, so optimism is priced in but not exhaustive. The data are fresh and specific, not vague, which raises the odds the FDA conversation shifts materially. We lean bullish because the studies solve concrete, previously flagged issues and the company kept the Q3 resubmission timeline. Conviction is tempered by remaining regulatory risk and the stock's intraday jump, so size exposure accordingly.